1983-81-9

Basic information

• Product Name: 4,7-DIHYDROXYCOUMARIN
• Synonyms: AURORA KA-3743;4,7-DIHYDROXYCOUMARIN;4,7-HYDROXY-COUMARIN;4,7-Dihydroxy-2H-1-benzopyran-2-one;4,7-Dihydroxy-2-oxo-2H-1-benzopyran;NSC 136214;4,7-Dihydroxychromen-4-one
• CAS NO: 1983-81-9
• Molecular Formula: C₉H₆O₄
• Molecular Weight: 178.14
• Mol File: 1983-81-9.mol
• Article Data: 22

Chemical Properties

• Melting Point: 280-281℃ (methanol )
• Boiling Point: 390°Cat760mmHg
• Flash Point: 166.5°C
• Appearance: /
• Density: 1.612g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.711
• Storage Temp.: 2-8°C
• PKA: 4.50±1.00(Predicted)
• CAS DataBase Reference: 4,7-DIHYDROXYCOUMARIN(CAS DataBase Reference)
• NIST Chemistry Reference: 4,7-DIHYDROXYCOUMARIN(1983-81-9)
• EPA Substance Registry System: 4,7-DIHYDROXYCOUMARIN(1983-81-9)

Safety Data

• Hazard Codes: Xi
• Statements: 22-36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 1983-81-9(Hazardous Substances Data)

Usage

General Description

4,7-Dihydroxycoumarin, also known as Aesculetin, is a chemical compound found in the class of organic compounds known as coumarins and derivatives. Coumarins are compounds containing the coumarin moiety, which consists of a benzene fused to a 2-pyrone to give 1-benzopyran-2-one. This simple coumarin is found in a variety of plants and some essential oils, and has a variety of biological activities, including anti-inflammatory, anticancer, and antidiabetic properties. Typically presented in a crystalline state, this compound is relatively safe to handle, but can potentially cause skin and eye irritations.

InChI:InChI=1/C9H6O4/c10-5-1-2-6-7(11)4-9(12)13-8(6)3-5/h1-4,10-11H

Upstream product

• 108-46-3 recorcinol 
• 29682-12-0 1-[4-(benzyloxy)-2-hydroxyphenyl]ethanone 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 30992-66-6 4-hydroxy-7-(phenylmethoxy)-2H-1-benzopyran-2-one 
• 141-82-2 malonic acid 
• 244049-27-2 4-amino-7-hydroxy-2H-chromen-2-one 
• 201230-82-2 carbon monoxide 
• 17575-15-4 4-hydroxy-7-methoxycoumarine 
• 552-41-0 1-(2-hydroxy-4-methoxyphenyl)ethanone 

Downstream Products

• 63360-23-6 4-(benzyloxy)-7-hydroxycoumarin 
• 1620389-04-9 C₁₇H₁₁F₃O₆S 
• 1620389-06-1 C₁₈H₁₃F₃O₆S 
• 1620389-07-2 C₁₈H₁₃F₃O₅S 
• 1620389-08-3 C₁₈H₁₃F₃O₅S 
• 1620389-09-4 C₁₆H₈F₄O₅S 
• 1620389-10-7 C₁₉H₁₅F₃O₈S 
• 1620389-11-8 C₁₇H₈F₆O₆S 
• 1620389-12-9 C₂₃H₁₈O₃ 
• 1620388-98-8 C₂₃H₁₈O₄ 
• 1620388-99-9 C₂₃H₁₈O₂ 
• 1620389-00-5 C₂₅H₂₂O₄ 
• 1620389-01-6 C₂₅H₂₂O₂ 
• 1620389-02-7 C₂₃H₁₂F₆O₂ 

Relevant articles and documents

-

-

Synthesis and biological evaluation of novel 4,7-dihydroxycoumarin derivatives as anticancer agents

A series of novel 4,7-dihydroxycoumarin based acryloylcyanohydrazone derivatives were synthesized and evaluated for antiproliferative activity against four different cancer cell lines (A549, HeLa, SKNSH, and MCF7). Most of the compounds displayed potent c

Synthesis and cytotoxic activities of novel 4-methoxy-substituted and 5-methyl-substituted (3′S,4′S)-(-)-cis-khellactone derivatives that induce apoptosis via the intrinsic pathway

This study deals with the design and synthesis of a series of novel 4-methoxy-substituted and 5-methyl-substituted (3′S,4′S)-(-)-cis-khellactones. The newly synthesized compounds were characterized by1H nuclear magnetic resonance (NMR),13

Design, synthesis, biological and in silico evaluation of coumarin-hydrazone derivatives as tubulin targeted antiproliferative agents

Coumarin-based different series of hydrazone derivatives were synthesized and evaluated for anticancer activity against four different human cancer cell lines. The activity of the compounds were compared with doxorubicin as a standard drug and all the compounds exhibited good to moderate cytotoxicity with IC50 values ranging from 6.07 to 60.45 μM against all the examined cancer cell lines. Based on the screening results, it was concluded that the compounds 12a and 18a were the most promising medicinal entities. In vitro tubulin polymerisation inhibition assay was performed for the compounds 12a and 18a and these two compounds displayed good potency when compared with colchicine as the standard drug. The interaction of these compounds with tubulin protein was also studied with the help of molecular docking technique using Discovery studio software. Furthermore, the molecular and ADMET properties of the compounds were computed with Osiris property software and PreADMET server. The compounds exhibited exciting in vitro and in silico results. Hence we propose that the compounds 12a and 18a could be developed as tubulin targeted potential antiproliferative agents.